ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ξγεεηϊ ςμ δϊεφΰεϊ μψαςεο δψΰωεο ωμ 20072/5/2007
δξλιψεϊ πθε ςμε α- 24% εδρϊλξε α- 2,080 ξμιεο $.
δψεεη δπχι δρϊλν α- 342 ξμιεο $ εδψεεη μξπιδ α- 0.42$, βιγεμ ωμ 20% ε- 14% αδϊΰξδ αδωεεΰδ μψεεη πχι ξϊεΰν εψεεη ξϊεΰν μξπιδ αψαςεο δψΰωεο ωμ 2006.
ϊζψιν ξζεξπιν ξτςιμεϊ ωεθτϊ ωμ 499 ξμιεο $.
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ γιεεηδ διεν ςμ ϊεφΰεϊ δψαςεο δψΰωεο ωδρϊιιν α- 31 αξψυ, 2007.
δξλιψεϊ πθε ωμ δψαςεο δψΰωεο δρϊλξε α- 2,080 ξμιεο $, βιγεμ ωμ 24% αδωεεΰδ μψαςεο δψΰωεο ωμ 2006. δξλιψεϊ δεωτςε δο ξδλμμϊ ψαςεο ωμν ωμ ξλιψεϊ ωμ Ivax, αδωεεΰδ μδλμμϊ ωπι ηεγωι ξλιψεϊ ωμ Ivax αψαςεο δξχαιμ ΰωϊχγ, εδο ξδϊηζχεϊ ωμ ξθαςεϊ ωεπιν, αξιεηγ ΰιψετΰιν, μςεξϊ δγεμψ.
ψεεη πχι μψαςεο δψΰωεο ωμ ωπϊ 2007 δρϊλν α- 342 ξμιεο $ εψεεη μξπιδ αγιμεμ ξμΰ δρϊλν α- 0.42$. δξρτψιν δξχαιμιν ωμ ωπϊ 2006, ςμ τι λμμι ηωαεπΰεϊ ξχεαμιν αΰψδ"α (US GAAP), λμμε ξηιχδ, μΰηψ ξρ, ωμ 1.3 ξιμιΰψγ $ δχωεψιν αςιχψ μψλιωϊ Ivax εξεψλαιν ξξε"τ αϊδμικ εωιςψεκ ξμΰι. ψεεη πχι εψεεη πχι μξπιδ μψαςεο δψΰωεο ωμ 2007 βγμε α- 20% ε- 14% αδϊΰξδ, αδωεεΰδ μψαςεο δψΰωεο ωμ 2006, μΰηψ δϊΰξεϊ ωμ ρςιτιν ΰμε. πϊεπιν ΰμε ωμ 2006 ΰιπν ςμ-τι λμμι δηωαεπΰεϊ δξχεαμιν αΰψδ"α (US GAAP). θας ξΰξιπδ λι δωιξεω απϊεπιν δξϊεΰξιν μτπι ρςιτιν ΰμε, ξριις μδαπδ θεαδ ιεϊψ ωμ δξβξεϊ δςρχιεϊ ωμ δηαψδ. μωιπειιν αωςψι δημιτιο διϊδ δωτςδ ξιπιξμιϊ ςμ δψεεη δπχι.
ωμξδ ιπΰι, πωιΰ εξπλ"μ θας ,δβια ςμ δϊεφΰεϊ: " ωπϊ 2007 δϊηιμδ ξφειο. δαιχεωιν δβαεδιν μϊψετεϊ βπψιεϊ αλμ δξγιπεϊ ωαδο ΰπε τεςμιν, ξλιψεϊ ωιΰ ψαςεπιεϊ ωμ δχετχρεο ®εδξωκ δφξιηδ δξεΰφϊ ωμ ξεφψι δπωιξδ ωμπε, δαιΰε ΰϊ ϊεφΰεϊ δψαςεο δψΰωεο ΰμ ξςαψ μφιτιεϊιπε".
ιπΰι δερισ:" διωβι δψαςεο ξωχτιν ΰϊ διιηεγιεϊ ωμ θας εΰϊ ιλεμϊπε μξπσ ΰϊ ξςξγπε λξεαιμι δωεχ δβπψι μδφμηεϊ αραιαδ ϊηψεϊιϊ εμξιχρεν δδζγξπειεϊ δψαεϊ δςεξγεϊ μτπιπε."
δξλιψεϊ δτψξφαθιεϊ αφτεο ΰξψιχδ (λεμμ χετχρεο®) διεε 51% ξρκ λμ δξλιψεϊ ωμ δηαψδ εδρϊλξε α- 1,071 ξμιεο $ αψαςεο αδωεεΰδ μ- 881 ξμιεο $ αψαςεο δψΰωεο ωμ ωπϊ 2006, βιγεμ ωμ 22%. δξλιψεϊ αψαςεο δψΰωεο δεωτςε ξξλιψεϊ βαεδεϊ ωμ oxycodone ε- bupropion XL, ξξλιψεϊ βαεδεϊ ιεϊψ ωμ ξεφψι πωιξδ ξξεϊβιν εξεφψιν ιηεγιιν (χετχρεο® εΰζιμχθ®).
δξλιψεϊ δτψξφαθιεϊ αΰιψετδ (λεμμ χετχρεο®) διεε 25% ξρκ λμ δξλιψεϊ ωμ δηαψδ εδρϊλξε α- 521 ξμιεο $, βιγεμ ωμ 37%. δξλιψεϊ ααψιθπιδ εφψτϊ αμθε αωιςεψ φξιηϊο εμλκ περτδ δδωτςδ ωμ δϊηζχεϊ δξθαςεϊ δΰιψετΰιν αδωεεΰδ μγεμψ δΰξψιχΰι. αςεγ θας πδπϊδ ξραιαδ ηιεαιϊ αωεεχιν δβπψιιν ωμ φψτϊ εβψξπιδ διΰ πϊχμδ αωεεχιν ξΰϊβψιν αδεπβψιδ εαΰιθμιδ.
ξλιψεϊ τψξφαθιεϊ αιπμΰεξιεϊ (λεμμ χετχρεο®), δλεμμεϊ αςιχψ ΰϊ ΰξψιχδ δμθιπιϊ (42%), ιωψΰμ (28%) εξγιπεϊ ξψλζ εξζψη ΰιψετδ (23%), βγμε δψαςεο α- 30% εδρϊλξε α- 340 ξμιεο $. δβιγεμ πας ξφξιηδ βγεμδ αΰξψιχδ δμθιπιϊ εξδωτςδ ηιεαιϊ ωμ ϊπεγεϊ ξθας.
χετχρεο® - δξλιψεϊ δβμεαμιεϊ ωμ χετχρεο®, αξεπηι ξηιψ ξλιψδ μωεχ, ςμε αψαςεο ζδ μψΰωεπδ ςμ 400 ξμιεο $, βιγεμ ωμ 22% αδωεεΰδ μψαςεο δξχαιμ α- 2006. δξλιψεϊ αΰψδ"α αξεπηι ξηιψ ξλιψδ μωεχ αψαςεο δψΰωεο βγμε α- 18% εδρϊλξε α- 260 ξμιεο $ εξωχτεϊ ςμιιϊ ξηιψιν εβιγεμ λξεϊι. δξλιψεϊ αξεπηι ξηιψ ξλιψδ μωεχ ξηευ μΰψδ"α, αςιχψ αΰιψετδ εχπγδ, βγμε α- 31% εδρϊλξε α- 141 ξμιεο $. δβιγεμ πεας ξωιτεψ αωεεχιν δΰιψετΰιν δξψλζιιν (βψξπιδ, φψτϊ εαψιθπιδ) εωςψι ημιτιο ηιεαιιν.
®Azilect - δξεφψ δξχεψι δωπι ωμ θας, δξωικ ΰϊ ηγιψϊε δξεφμηϊ μωεχ εζελδ μδλψδ δεμλϊ εβγμδ λημετδ ιςιμδ μξεφψιν δχιιξιν μθιτεμ αξημϊ δτψχιπρεο αΰψδ"α εαΰιψετδ ςν ξλιψεϊ βμεαμιεϊ αξεπηι ξηιψ ξλιψδ μωεχ αψαςεο ωμ 25 ξμιεο $ αδωεεΰδ μ- 19 ξμιεο $ αψαςεο δψαιςι ωμ 2006 ε- 3 ξμιεο $ αψαςεο δψΰωεο ωμ 2006. ΰζιμχθ® ξΰεωψ λςϊ μωιξεω α- 26 ξγιπεϊ, λεμμ αΰιθμιδ αδ δεωχ αξδμκ δψαςεο.
δξλιψεϊ δβμεαμιεϊ ωμ ξεφψι δπωιξδ αξδμκ δψαςεο δψΰωεο ωμ 2007 δρϊλξε α- 193 ξμιεο $, βιγεμ ωμ ιεϊψ ξλτμιιν αιηρ μϊχετδ δξχαιμδ ΰωϊχγ. δβιγεμ πας αψεαε ξβιγεμ ξωξςεϊι ωμ ξλιψεϊ ProAir (albuterol HFA) αΰψδ"α δπεας ξϊδμικ δξςαψ δξδιψ μξωΰτιν ωΰιπν ξαερρι CFC εξπϊηδ δβαεδ ωμ θας αωεχ.
ξλιψεϊ δλιξιδ (API) μφγγιν ωμιωιιν, ωμ 148 ξμιεο $, πωΰψε αΰεϊδ δψξδ ωμ δψαςεο δξχαιμ ΰωϊχγ. λμμ ξλιψεϊ δ- API, λεμμ ξλιψεϊ μιηιγεϊ δτπιξιεϊ ωμ θας, δρϊλξε α- 336 ξμιεο $ δψαςεο.
δεφΰεϊ ξηχψ ετιϊεη (ξε"τ) πθε βγμε α- 31% εδρϊλξε α- 135 ξμιεο $ (6.5% ξξλιψεϊ πθε) εξωχτεϊ αςιχψ βιγεμ αδεφΰεϊ ξε"τ βπψι. α- 23 αΰτψιμ, 2007, μθας διε 151 αχωεϊ δξξϊιπεϊ μΰιωεψ ρετι ωμ ψωεϊ δξζεο εδϊψετεϊ δΰξψιχΰιϊ (FDA). ρκ δξλιψεϊ δωπϊιεϊ ωμ αχωεϊ ΰμδ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, διπε λ- 90 ξμιΰψγ $. θας ξΰξιπδ λι διπδ δψΰωεπδ μδβιω αχωδ μΰιωεψ ςαεψ 42 ξεφψιν ξϊεκ αχωεϊ ΰμδ, δξωχτιν ξλιψεϊ ωπϊιεϊ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, ωμ ξςμ μ- 35 ξμιΰψγ $.
ωιςεψ δξρ ωπχας αψαςεο ζδ ωμ 18% ξδδλπρδ μτπι ξρ, ξιιφβ ΰϊ δςψλϊπε δπεληιϊ μωιςεψ δξρ μωπϊ 2007 λεμδ αδωεεΰδ μωιςεψ ωμ 19% μψαςεο δψΰωεο ωμ ωπϊ 2006 ε- 15% ξδδλπρδ δξεϊΰξϊ μτπι ξρ αωπϊ 2006 λεμδ. ωιςεψ ζδ ξωχσ ϊξδιμ δλπρεϊ ωεπδ, λεμμ ξλιψεϊ βαεδεϊ ιεϊψ ωμ ξεφψιν ωξχεψν αΰψδ"α.
ϊζψιν δξζεξπιν ξτςιμεϊ ωεθτϊ αψαςεο δψΰωεο ωμ 2007 δρϊλν α- 499 ξμιεο $. ϊζψιν ξζεξπιν ηετωι (Free Cash Flow) δρϊλν α- 278 ξμιεο $. ωεει ξζεξπιν επιιψεϊ ςψκ ρηιψιν μιεν 31 αξψυ, 2007 διδ 2.6 ξμιΰψγ $.
ψλιωϊ ξπιεϊ αξδμκ δψαςεο δψΰωεο ωμ 2007, θας ψλωδ 3.4 ξμιεο ξξπιεϊιδ αρλεν λεμμ ωμ 152 ξμιεο $. αξφθαψ, ξΰζ ΰιωεψ δγιψχθεψιο ξϊΰψικ 7 απεαξαψ, 2006 μψλεω ξπιεϊ αρλεν ωμ ςγ 600 ξμιεο $, θας ψλωδ λ- 11.7 ξμιεο ξπιεϊ αρλεν ωμ 386 ξμιεο $, δξωχτιν ξηιψ ψλιωδ ξξεφς ωμ 32.90$ μξπιδ.
ξρτψ δξπιεϊ - πλεο μψαςεο δψΰωεο ωμ 2007, ξρτψ δξπιεϊ μφεψκ ηιωεα δψεεη δπχι μξπιδ αγιμεμ ξμΰ, διπε 827 ξμιεο ξπιεϊ. πλεο μ- 31 αξψυ, 2007, ξρτψ δξπιεϊ μφεψκ ηιωεα ξρτψ δξπιεϊ αγιμεμ ξμΰ ξεςψκ α- 827 ξμιεο ξπιεϊ.
(Outlook δπηιεϊ μβαι ϊηζιεϊ δηαψδ μωπϊ 2007 ιπϊπε αωιηϊ δεεςιγδ (τψθιν μδμο.
γιαιγπγ
γιψχθεψιεο δηαψδ, αιωιαϊε αιεν 1 αξΰι, 2007, δλψιζ ςμ ϊωμεν γιαιγπγ αξζεξο αβιο δψαςεο δψΰωεο ωμ ωπϊ 2007, αωιςεψ ωμ 0.40 ω"η μξπιδ (λ- 10 ρπθ ςμ τι ωςψ δγεμψ α- 1 αξΰι, 2007). διεν δχεας ιδιδ α- 14 αξΰι, 2007 ειεν δϊωμεν πχας μ- 29 αξΰι, 2007. ωιςεψ δξρ ωιπελδ αξχεψ ιδιδ 16%.
τψθι ωιηϊ δεςιγδ
δπδμϊ θας ϊχιιν ωιηϊ εςιγδ αιεν ψαιςι, 2 αξΰι, 2007, αωςδ 15:30 ωςεο ιωψΰμ (08:30 ωςεο πιε-ιεψχ) ΰωψ αδ ιιρχψε ϊεφΰεϊ δψαςεο δψΰωεο ωμ 2007. πιϊο μδΰζιο μωιηδ γψκ ΰϊψ δΰιπθψπθ ωμ θας, αλϊεαϊ : www.tevapharm.com. πιϊο ιδιδ μδΰζιο μωιγεψ ηεζψ ςγ μιεν 9 αξΰι, 2007 αηφεϊ (ωςεο πιε-ιεψχ) αΰϊψ δηαψδ, ΰε ςμ-ιγι ηιεβ 1-877-660-6853 μξηιιβιν αϊεκ ΰψδ"α ε- 1-201-612-7415 μξηιιβιν ξηευ μΰψδ"α. χεγ δλπιρδ μωιγεψ δηεζψ διπε ηωαεο ξρτψ (Account #) 3055 ε- ϊε δζιδει (ID#) διπε: 238370.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20 δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ, ιιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ εξεφψιν εεθψιπψιν, διπδ δηαψδ δξεαιμδ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο εαξψλζ ΰξψιχδ εαΰιψετδ. ιεϊψ ξ- 80% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: whether and when the proposed acquisition of CoGenesys will be consummated, whether and when Teva will obtain HSR approval for the acquisition and any conditions that could be imposed in connection with such approval, Teva's ability to rapidly integrate CoGenesys' operations with its own operations, the diversion of management time on merger-related issues, and Teva and CoGenesys' ability to successfully develop and commercialize biopharmaceutical products, Teva's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir®, and Protonix®, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: whether and when the proposed acquisition of CoGenesys will be consummated, whether and when Teva will obtain HSR approval for the acquisition and any conditions that could be imposed in connection with such approval, Teva's ability to rapidly integrate CoGenesys' operations with its own operations, the diversion of management time on merger-related issues, and Teva and CoGenesys' ability to successfully develop and commercialize biopharmaceutical products, Teva's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir®, and Protonix®, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |